Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Effectiveness of Rimegepant for Acute Treatment of Migraine in Adults Unsuitable for Triptan Use: Results from a 12-week Open-label Extension Phase.

Reasons for Discontinuing Triptans Among Current Users of Rimegepant for the Acute Treatment of Migraine in the CONFIDENCE Study